|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LEF1 |
Gene summary for LEF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LEF1 | Gene ID | 51176 |
| Gene name | lymphoid enhancer binding factor 1 | |
| Gene Alias | LEF-1 | |
| Cytomap | 4q25 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q659G9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51176 | LEF1 | LZE7T | Human | Esophagus | ESCC | 3.99e-05 | 1.79e-01 | 0.0667 |
| 51176 | LEF1 | P2T-E | Human | Esophagus | ESCC | 1.08e-21 | 4.94e-01 | 0.1177 |
| 51176 | LEF1 | P4T-E | Human | Esophagus | ESCC | 2.03e-18 | 4.82e-01 | 0.1323 |
| 51176 | LEF1 | P9T-E | Human | Esophagus | ESCC | 9.84e-07 | 2.32e-01 | 0.1131 |
| 51176 | LEF1 | P10T-E | Human | Esophagus | ESCC | 3.43e-16 | 4.18e-01 | 0.116 |
| 51176 | LEF1 | P12T-E | Human | Esophagus | ESCC | 4.80e-02 | 1.21e-01 | 0.1122 |
| 51176 | LEF1 | P15T-E | Human | Esophagus | ESCC | 5.02e-12 | 1.95e-01 | 0.1149 |
| 51176 | LEF1 | P16T-E | Human | Esophagus | ESCC | 3.63e-28 | 5.39e-01 | 0.1153 |
| 51176 | LEF1 | P23T-E | Human | Esophagus | ESCC | 6.85e-11 | 3.79e-01 | 0.108 |
| 51176 | LEF1 | P26T-E | Human | Esophagus | ESCC | 8.98e-20 | 3.52e-01 | 0.1276 |
| 51176 | LEF1 | P27T-E | Human | Esophagus | ESCC | 2.75e-29 | 6.33e-01 | 0.1055 |
| 51176 | LEF1 | P28T-E | Human | Esophagus | ESCC | 4.46e-04 | 1.53e-01 | 0.1149 |
| 51176 | LEF1 | P30T-E | Human | Esophagus | ESCC | 6.92e-04 | 2.79e-01 | 0.137 |
| 51176 | LEF1 | P32T-E | Human | Esophagus | ESCC | 1.89e-07 | 1.88e-01 | 0.1666 |
| 51176 | LEF1 | P39T-E | Human | Esophagus | ESCC | 2.79e-04 | 1.50e-01 | 0.0894 |
| 51176 | LEF1 | P42T-E | Human | Esophagus | ESCC | 1.78e-14 | 3.63e-01 | 0.1175 |
| 51176 | LEF1 | P48T-E | Human | Esophagus | ESCC | 4.05e-03 | 2.09e-01 | 0.0959 |
| 51176 | LEF1 | P52T-E | Human | Esophagus | ESCC | 1.57e-07 | 4.37e-01 | 0.1555 |
| 51176 | LEF1 | P54T-E | Human | Esophagus | ESCC | 5.94e-05 | 1.71e-01 | 0.0975 |
| 51176 | LEF1 | P56T-E | Human | Esophagus | ESCC | 5.36e-07 | 1.05e+00 | 0.1613 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
| GO:0051101111 | Esophagus | ESCC | regulation of DNA binding | 84/8552 | 118/18723 | 1.64e-08 | 3.21e-07 | 84 |
| GO:0051100111 | Esophagus | ESCC | negative regulation of binding | 109/8552 | 162/18723 | 2.10e-08 | 4.03e-07 | 109 |
| GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0521020 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
| hsa05167211 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa0521628 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
| hsa0521320 | Esophagus | ESCC | Endometrial cancer | 45/4205 | 58/8465 | 1.14e-05 | 5.98e-05 | 3.06e-05 | 45 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa052215 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa05210110 | Esophagus | ESCC | Colorectal cancer | 69/4205 | 86/8465 | 4.06e-09 | 4.13e-08 | 2.11e-08 | 69 |
| hsa0516738 | Esophagus | ESCC | Kaposi sarcoma-associated herpesvirus infection | 136/4205 | 194/8465 | 4.28e-09 | 4.22e-08 | 2.16e-08 | 136 |
| hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
| hsa05213110 | Esophagus | ESCC | Endometrial cancer | 45/4205 | 58/8465 | 1.14e-05 | 5.98e-05 | 3.06e-05 | 45 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| LEF1 | MLUM | Breast | DCIS | KCNE4,ZNF385D,RHOBTB3, etc. | 6.41e-01 |  |
| LEF1 | TFH | Breast | DCIS | MAL,TCF7,LDHB, etc. | 8.56e-02 | |
| LEF1 | CD4TN | Breast | DCIS | MAL,TCF7,LDHB, etc. | 2.85e-01 | |
| LEF1 | TH17 | Breast | DCIS | MAL,TCF7,LDHB, etc. | 4.54e-02 | |
| LEF1 | CD8TEXINT | Breast | Healthy | MAL,TCF7,LDHB, etc. | 1.36e-01 |  |
| LEF1 | CD4TN | Breast | IDC | MAL,TCF7,LDHB, etc. | 1.21e-01 |  |
| LEF1 | TFH | Breast | IDC | MAL,TCF7,LDHB, etc. | 1.43e-01 | |
| LEF1 | TH17 | Breast | IDC | MAL,TCF7,LDHB, etc. | 4.90e-02 | |
| LEF1 | CD8TCM | Breast | Precancer | MAL,TCF7,LDHB, etc. | 5.86e-01 |  |
| LEF1 | TFH | Cervix | CC | TCF7,TRABD2A,MAL, etc. | 5.58e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 4 5 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LEF1 | SNV | Missense_Mutation | c.194C>T | p.Pro65Leu | p.P65L | Q9UJU2 | protein_coding | deleterious(0.01) | possibly_damaging(0.511) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| LEF1 | insertion | Nonsense_Mutation | novel | c.449_450insTGAGTTTGAGAGGGAGGACCAGTCTTGGTCGTGGTGAATTTGAAGT | p.Val151GlufsTer12 | p.V151Efs*12 | Q9UJU2 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| LEF1 | SNV | Missense_Mutation | rs377048071 | c.706G>A | p.Asp236Asn | p.D236N | Q9UJU2 | protein_coding | tolerated(1) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LEF1 | SNV | Missense_Mutation | novel | c.145G>A | p.Asp49Asn | p.D49N | Q9UJU2 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LEF1 | SNV | Missense_Mutation | c.826N>A | p.Asp276Asn | p.D276N | Q9UJU2 | protein_coding | tolerated(0.19) | benign(0.009) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LEF1 | SNV | Missense_Mutation | rs146861754 | c.745G>A | p.Gly249Ser | p.G249S | Q9UJU2 | protein_coding | tolerated(0.45) | benign(0.079) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| LEF1 | SNV | Missense_Mutation | c.362N>G | p.Asn121Ser | p.N121S | Q9UJU2 | protein_coding | tolerated(0.54) | benign(0.017) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LEF1 | SNV | Missense_Mutation | novel | c.788N>C | p.Ile263Thr | p.I263T | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LEF1 | SNV | Missense_Mutation | c.914N>T | p.Ala305Val | p.A305V | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
| LEF1 | SNV | Missense_Mutation | novel | c.916N>C | p.Phe306Leu | p.F306L | Q9UJU2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |